LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies

Journal of Biological Chemistry

Volumn 287, Issue 52, 2012, Pages 43331-43339

  Wranik, Bernd J ^a   Christensen, Erin L ^a   Schaefer, Gabriele ^a   Jackman, Janet K ^a   Vendel, Andrew C ^a,b   Eaton, Dan ^a  

^a GENENTECH INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C TERMINUS; HEAVY CHAIN; HUMAN IGG; LEUCINE ZIPPERS; LIGHT CHAIN; MAMMALIAN CELL PRODUCTION; PEPTIDE TETHER; SINGLE-POINT MUTATION; STRUCTURAL SIMILARITY;

BIOACTIVITY; PURIFICATION; TRANSCRIPTION FACTORS;

ANTIBODIES;

BISPECIFIC ANTIBODY; HETERODIMER; IMMUNOGLOBULIN G ANTIBODY; LEUCINE ZIPPER PROTEIN; LUZ Y ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONTROLLED STUDY; HEAVY CHAIN; LIGHT CHAIN; MAMMAL CELL; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAT;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; CELL LINE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; POINT MUTATION; PROTEIN ENGINEERING;

MAMMALIA;

EID: 84871565611     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.397869     Document Type: Article

References (25)

1. Staerz, U. D., Kanagawa, O., and Bevan, M. J. (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314, 628-631 (Pubitemid 15080840)
2. Staerz, U. D., and Bevan, M. J. (1986) Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl. Acad. Sci. U.S.A. 83, 1453-1457 (Pubitemid 16016147)
3. Kontermann, R. E. (2010) Alternative antibody formats. Curr. Opin. Mol. Ther 12, 176-183
4. Fischer, N., and Léger, O. (2007) Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 74, 3-14 (Pubitemid 46742313)
5. Hollander, N. (2009) Bispecific antibodies for cancer therapy. Immunotherapy 1, 211-222
6. Ridgway, J. B., Presta, L. G., and Carter, P. (1996) 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617-621 (Pubitemid 26241639)
7. Davis, J. H., Aperlo, C., Li, Y., Kurosawa, E., Lan, Y., Lo, K-M., and Houston, J. S. (2010) SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Engineering, Design and Selection 23, 195-202
8. Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S. B., Born, T., Retter, M., Manchulenko, K., Sweet, H., Foltz, I. N., Wittekind, M., and Yan, W. (2010) Enhancing antibody Fc heterodimer formation through electrostatic steering effects. J. Biol. Chem. 285, 19637-19646
9. Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., and Carter, P. (1998) An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677-681 (Pubitemid 28334328)
10. Schaefer, W., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., Schwaiger, M., Stubenrauch, K. G., Sustmann, C., Thomas, M., Scheuer, W., and Klein, C. (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. U.S.A. 108, 11187-11192
11. Bostrom, J., Yu, S. F., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., and Fuh, G. (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614
12. Kostelny, S. A., Cole, M. S., and Tso, J. Y. (1992) Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 148, 1547-1553
13. de Kruif, J., and Logtenberg, T. (1996) Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J. Biol. Chem. 271, 7630-7634
14. Li, J. S., Cui, L., Rock, D. L., and Li, J. (2005) Novel glycosidic linkage in Aedes aegypti chorion peroxidase. J. Biol. Chem. 280, 38513-38521 (Pubitemid 43853750)
15. Pruss, R. M., Herschman, H. R., and Klement, V. (1978) 3T3 variants lacking receptors for epidermal growth factor are susceptible to transformation by Kirsten sarcoma virus. Nature 274, 272-274 (Pubitemid 8378035)
16. Schaefer, G., Shao, L., Totpal, K., and Akita, R. W. (2007) Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res. 67, 1228-1238
17. O'Shea, E. K., Lumb, K. J., and Kim, P. S. (1993) Peptide 'Velcro': design of a heterodimeric coiled coil. Curr. Biol. 3, 658-667
18. Wines, B. D., Powell, M. S., Parren, P. W., Barnes, N., and Hogarth, P. M. (2000) The IgG Fc contains distinct Fc receptor (FcR) binding sites: The leukocyte receptors Fc-RI and Fc-RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J. Immunol. 164, 5313-5318 (Pubitemid 30305210)
19. Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., Clark, R., Fields, C., Lewis Phillips, G. D., Prell, R. A., Danilenko, D. M., Franke, Y., Stephan, J. P., Hwang, J., Wu, Y., Bostrom, J., Sliwkowski, M. X., Fuh, G., and Eigenbrot, C. (2011) A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20, 472-486
20. Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., and Ullrich, A. (1989) p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9, 1165-1172 (Pubitemid 19071685)
21. Jackman, J., Chen, Y., Huang, A., Moffat, B., Scheer, J. M., Leong, S. R., Lee, W. P., Zhang, J., Sharma, N., Lu, Y., Iyer, S., Shields, R. L., Chiang, N., Bauer, M. C., Wadley, D., Roose-Girma, M., Vandlen, R., Yansura, D. G., Wu, Y., and Wu, L. C. (2010) Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J. Biol. Chem. 285, 20850-20859
22. Wilson, T. R., Lee, D. Y., Berry, L., Shames, D. S., and Settleman, J. (2011) Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 20, 158-172
23. Krysan, D. J., Rockwell, N. C., and Fuller, R. S. (1999) Quantitative characterization of furin specificity. J. Biol. Chem. 274, 23229-23234
24. Harris, R. J. (1995) Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J. Chromatogr. A 705, 129-134
25. Kuwada, S. K., Scaife, C. L., Kuang, J., Li, X., Wong, R. F., Florell, S. R., Coffey, R. J., Jr., and Gray, P. D. (2004) Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int. J. Cancer 109, 291-301 (Pubitemid 38240934)